Nitroglycerin
Nitro-dur, Nitroglycerin, Nitrolingual Pumpspray, Nitromist, Nitrostat, Rectiv (nitroglycerin) is a small molecule pharmaceutical. Nitroglycerin was first approved as Nitroglycerin on 1982-01-01. It is used to treat angina pectoris, diffuse esophageal spasm, eclampsia, fissure in ano, and heart failure amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Nitro-dur, Nitroglycerin, Nitrolingual pumpspray, Nitromist, Nitrostat, Rectiv (discontinued: Gonitro, Minitran, Nitro, Nitro-bid, Nitroglycerin, Nitrol, Nitrolingual pumpspray, Nitrostat, Transderm-nitro, Tridil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nitroglycerin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RECTIV | AbbVie | N-021359 RX | 2011-06-21 | 1 products, RLD, RS |
| NITROGLYCERIN IN DEXTROSE 5% | Baxter | N-019970 RX | 1989-12-29 | 3 products, RLD, RS |
| NITROMIST | Evus Health Solutions | N-021780 RX | 2006-11-02 | 1 products, RLD, RS |
| NITROLINGUAL PUMPSPRAY | Pohl-Boskamp | N-018705 RX | 1997-01-10 | 1 products, RLD, RS |
| NITRO-DUR | USpharma | N-020145 RX | 1995-04-04 | 6 products, RLD, RS |
| NITROSTAT | Viatris | N-021134 RX | 2000-05-01 | 3 products, RLD, RS |
Show 10 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| basic dental emergency kit | unapproved drug other | 2024-10-03 |
| deluxe dental emergency kit | unapproved drug other | 2024-10-03 |
| gonitro | New Drug Application | 2018-06-20 |
| minitran | Export only | 2025-01-15 |
| nitro-bid | ANDA | 2024-09-04 |
| nitro-dur | New Drug Application | 2023-05-30 |
| nitro-time | unapproved drug other | 2018-10-09 |
| nitroglycerin | ANDA | 2025-02-10 |
| nitroglycerin in dextrose | New Drug Application | 2022-12-09 |
| nitroglycerin in dextrose | New Drug Application | 2016-08-22 |
Show 9 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
641 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Transposition of great vessels | D014188 | — | Q20.3 | — | — | — | 1 | — | 1 |
| Arterial switch operation | D000069278 | — | — | — | — | — | 1 | — | 1 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | — | — | 1 | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | — | 1 | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | 1 | — | — | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nitroglycerin |
| INN | — |
| Description | Nitroglycerin is a nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain. It has a role as a vasodilator agent, a nitric oxide donor, an explosive, a prodrug, a tocolytic agent, a muscle relaxant and a xenobiotic. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-] |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Nitroglycerin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,533 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nitro-dur, Nitroglycerin transdermal infusion system
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,015 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use